NHTSA Report: Alcohol and Drug Prevalence Among Seriously or Fatally Injured Road Users
About this document
- Layer
- attachment: a document a meeting packet links to
- Type as titled
- publication (kind from doc_type)
- File
- 3a0160e9792366039c4c24908c2d7e1cb47c0353 application/pdf
- Cases
About: Jaime Bermudez (case)
Limitations
This study selected seven sites that included high-volume trauma centers servicing large catchment areas, and was able to enlist MEs at four of those sites to assist the study. These sites were not a random sample of all Level 1 trauma centers across the country. As such, no inferences can be made regarding the applicability of the study findings beyond the populations served by these trauma centers and MEs. Because of the rolling start to data collection, inherent patient flow rate differences, and availability of staff during the public health emergency, some sites provided more specimens to the study than others. In addition, the onset of the COVID-19 public health emergency meant that some sites provided cases before the pandemic while others only provide cases during. These issues limit any comparisons across sites and certainly introduces some level of bias in the reported raw prevalence rates when data are combined across all sites for the entire study period. In addition, the ME results are biased toward fatalities in Maryland where the ME's office services the entire State. Because of this, 73.9% of all road user ME cases came from Maryland.
This study operated under the assumption that on-site research staff at the trauma centers and MEs checked the criteria for inclusion for each participant. Although strict criteria for inclusion were provided, it is possible that some cases did not meet the time from crash criterion due to a lack of information from EMS or unavailability of a crash report, especially during the COVID-19 public health emergency when access to patient care areas was greatly restricted for research of this type. The study did examine drug prevalence rates for included cases without a known time from crash to blood draw and found the prevalence patterns to be virtually identical to those when a time could be calculated. Still, future research will need to take this issue into consideration if similar restrictions on access to patient care areas remain in place.
As noted in the report, this study had to change its specimen collection and processing approach at the trauma centers during the public health emergency in order to provide viable specimens to NIH for COVID-19 antibody testing. The change involved first collecting specimens in a lavender-top tube and then splitting the sample into a gray-top for toxicological testing with the remainder in the lavender-top processed for plasma. In theory, the additional preservative found in the lavender-top tube could have affected the detection of drugs. Study staff closely monitored the patterns of results after the change in procedures and concluded the impact on study results was likely minimal if there was any impact at all. More laboratory research is needed to determine the degree to which such procedures could affect toxicological findings.
Overall, this study's results can only be used to describe the prevalence of drug positivity among the specific populations sampled and with full awareness of the study's design limitations. Without a matched control group or other basis for comparison to similar, non-injured, non-crash-involved roadway users, it is not possible to determine if any of the drugs studied here are associated with an increased risk of being seriously injured or killed in a motor vehicle crash. The study results should not be used to imply impairment or increased risk associated with drug presence.
44
Keys: ← → or j k turn pages; / finds.